国际共识:早期剂量探索肿瘤试验中患者报告结局研究目标建议
OPTIMISE-ROR项目基于EQUATOR框架制定指南,通过方法学综述、专家咨询、两轮国际多利益相关方Delphi调查(第一轮109人,第二轮96人)及共识会议(31人),就早期剂量探索肿瘤试验中患者报告结局(PRO)的研究目标达成六条推荐,强调PRO耐受性概念、剂量推荐整合及纵向数据分析。
要点
- 推荐关注三个核心PRO耐受性概念:总体副作用影响、症状性不良事件和总体健康相关生活质量。
- 无论试验设计如何,应考虑整合PRO以支持剂量递增和优化试验的最终剂量推荐。
- 应定义PRO研究目标为描述性或统计效能性,并评估PRO相关终点以指导后续研究终点选择。
核心结论
- 该指南为早期剂量探索肿瘤试验中PRO研究目标提供了基础性指导,支持系统整合PRO以用于耐受性和疗效评估,从而指导剂量递增、优化和监管评价。
主要发现
- 共识达成六条推荐,强调三个核心PRO耐受性概念:总体副作用影响、症状性不良事件和总体健康相关生活质量。
- 推荐无论试验设计如何,应考虑整合PRO以支持剂量递增和优化试验的最终剂量推荐。
- 推荐强调纵向和跨剂量水平分析PRO数据的重要性,定义PRO研究目标为描述性或统计效能性,并评估PRO相关终点以指导后续研究终点选择。
关键数值与推荐
- 共识推荐六条,聚焦三个核心PRO耐受性概念:总体副作用影响、症状性不良事件和总体健康相关生活质量。
- 推荐考虑整合PRO以支持剂量递增和优化试验的最终剂量推荐, regardless of trial design。
- 推荐定义PRO研究目标为描述性或统计效能性,并评估PRO相关终点以指导后续研究终点选择。
临床怎么用
- 在早期剂量探索试验中系统整合PRO,以评估耐受性、指导剂量选择并优化后续试验设计。
- 将PRO研究目标明确为描述性或统计效能性,并纵向跨剂量水平分析PRO数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: There is growing scientific interest in incorporating patient-reported outcomes (PROs) in early phase dose-finding oncology trials (DFOTs) to assess tolerability, inform dose selection, and guide later stage trial design. However, research indicates that PRO objectives in DFOTs are often unclear. The Incorporating Patient-Reported Outcomes in Dose-Finding Trials-Research Objectives Recommendations (OPTIMISE-ROR) project was established to support trialists to effectively incorporate PROs into DFOTs. METHODS: Using the Enhancing Quality and Transparency of Health Research (EQUATOR) Network's methodological framework, guideline development included the following: (1) a methodological review of published DFOTs incorporating PROs; (2) candidate item generation, refined through expert consultation; (3) a two-round international multistakeholder Delphi survey (N = 109 in Round 1 [October 2024]; N = 96 in Round 2 [December 2024]); and (4) an independently chaired virtual consensus meeting (N = 31; January 2025) where multidisciplinary, international experts reviewed and voted to finalize items for inclusion. RESULTS: Consensus was reached on six recommendations emphasizing three core PRO tolerability concepts: overall side effect impact, symptomatic adverse events, and overall health-related quality of life. The integration of PROs to inform final dose recommendations in dose escalation and optimization trials should be considered, regardless of trial design. The recommendations highlight the importance of PRO data analysis over time and across dose levels, defining PRO research objectives as descriptive or statistically powered, and assessing PRO-related end points to guide end point selection for subsequent studies. CONCLUSION: This foundational guidance outlines key PRO research objectives in DFOTs. By facilitating the systematic integration of PROs, this guidance supports the utilization of patient-centered evidence for the tolerability and efficacy assessment of therapies to inform dose escalation, optimization, and regulatory evaluation-ultimately contributing to the development of safer, more effective therapies.
引用
- Alger E, Aiyegbusi OL, Dueck AC, et al. International Consensus-Driven Recommendations for Patient-Reported Outcome Research Objectives in Early Phase Dose-Finding Oncology Trials: OPTIMISE-ROR. J Clin Oncol. 2026. PMID: 41576310. doi:10.1200/JCO-25-01625
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。